X

Trial Profile

A phase I study of PGG-glucan in healthy human volunteers

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 17 Mar 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Odetiglucan (Primary)
Indications Breast cancer; Chronic lymphocytic leukaemia; Colorectal cancer; Follicular lymphoma; Head and neck cancer; Malignant melanoma; Myelosuppression; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Pancreatic cancer
Focus Pharmacodynamics

Most Recent Events

17 Mar 2017 New trial record
24 Feb 2017 According to a Biothera media release, results from the study were delivered in a poster presentation at the American Society of Clinical Oncology (ASCO) - Society for Immunotherapy of Cancer (SITC) Clinical Immuno-Oncology Symposium.
24 Feb 2017 Results published in a Biothera media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com